Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A compound of formula I



I

in free or salt form, where

R^1 is a monovalent aromatic group having up to 10 carbon atoms; and

R^2 and R^3 together with the nitrogen atom to which they are attached denote a heterocyclic group having up to 10 ring atoms and having 1 to 4 hetero atoms in the ring system.

2. (Previously Presented) A compound according to claim 1, in which

R^1 is phenyl substituted by one or two substituents selected from cyano, halogen, carboxy or C_1-C_4-haloalkoxy, and optionally by C_1-C_4-alkyl or C_1-C_4-alkoxy, or R^1 is phenyl substituted by C_1-C_4-alkoxy; and

R^2 and R^3 together with the nitrogen atom to which they are attached denote a heterocyclic group having up to 6 ring atoms and one or two hetero atoms in the ring.

3. (Previously Presented) A compound according to claim 1, in which

R^1 is phenyl substituted by one or two substituents selected from cyano, halogen, carboxy or C_1-C_4-haloalkoxy meta to the indicated naphthyridine ring and optionally by C_1-C_4-alkyl or C_1-C_4-alkoxy ortho to the indicated naphthyridine ring, or R^1 is phenyl substituted by C_1-C_4-alkoxy meta to the indicated naphthyridine ring; and

R^2 and R^3 together with the nitrogen atom to which they are attached denote a heterocyclyl group having up to 6 ring atoms and one or two nitrogen atoms, or one nitrogen atom and one oxygen atom, in the ring, optionally substituted by hydroxy, carboxy, 5-membered O-heterocyclylcarbonyl, aminocarbonyl, C_1-C_4-alkoxycarbonyl, C_1-C_4-alkylsulfonyl or C_1-C_4-alkyl optionally substituted by hydroxy, cyano, carboxy or C_1-C_4-alkoxycarbonyl.

4. (Previously Presented) A compound according to claim 1 in which

R^1 is phenyl optionally substituted by one, two or three substituents selected from the group consisting of cyano, C_1-C_8-alkyl, C_1-C_8-alkylthio, -SO-C_1-C_8-alkyl, and phenyl fused with a heterocyclic ring having 3 to 8 ring atoms of which up to 4 can be carbon atoms and up to 4 can be hetero atoms; and

R^2 and R^3 together with the nitrogen atom to which they are attached denote a heterocyclic group having up to 6 ring atoms and one or two hetero atoms in the ring optionally substituted by carboxy, carboxy-C_1-C_8-alkoxy or C_1-C_8-alkoxycarbonyl-C_1-C_8-alkoxy, said heterocyclic group also optionally being substituted by C_1-C_8-alkyl or C_1-C_8-alkoxy.

5. (Previously Presented) A compound according to claim 4, in which

R^1 is phenyl optionally substituted by one, two or three substituents selected from the group consisting of cyano, C_1-C_4-alkyl, C_1-C_4-alkylthio, -SO-C_1-C_4-alkyl, and phenyl fused with a heterocyclic ring having 5 or 6 ring atoms of which up to 4 can be carbon atoms and up to 2 can be hetero atoms; and

R^2 and R^3 together with the nitrogen atom to which they are attached denote a heterocyclic group having up to 6 ring atoms and one or two nitrogen atoms in the ring optionally substituted by carboxy, carboxy- C_1-C_4-alkoxy or C_1-C_4-alkoxycarbonyl-C_1-C_4-alkoxy, said heterocyclic group also optionally being substituted by C_1-C_4-alkyl.

6. (Original) A compound according to claim 1, which is

3-[6-(3-hydroxy-pyrrolidin-1-yl)-[1,7]naphthyridin-8-yl]-benzonitrile;

3-{6-[4-(2-cyano-ethyl)-piperazin-1-yl]-[1,7]naphthyridin-8-yl}-benzonitrile;

1-[8-(3-cyano-phenyl)-[1,7]naphthyridin-6-yl]-piperidine-4-carboxylic acid, lithium salt; or

3-(6-piperazin-1-yl-[1,7]naphthyridin-8-yl)-benzonitrile;

1-[8-(3-fluoro-phenyl)-[1,7]naphthyridin-6-yl]-piperidine-4-carboxylic acid ethyl ester;

sodium 1-[8-(3-fluoro-phenyl)-[1,7]naphthyridin-6-yl]-piperidine-4-carboxylate;

1-[8-(5-fluoro-2-methoxy-phenyl)-[1,7]naphthyridin-6-yl]-piperidine-4-carboxylic acid ethyl ester; or

potassium 1-[8-(5-fluoro-2-methoxy-phenyl)-[1,7]naphthyridin-6-yl]-piperidine-4-carboxylate.

7. (Original) A compound according to claim 1, wherein R^1 and -NR^2R^3 are as shown in the following table:

R^1	NR^2R^3

	
	
	
	
	
	
	
	
	
	
	

 C≡N	 N CO2H N
 C≡N	 N OC2H5 HN O
 C≡N	 SO2CH3 N N
 C≡N	 CH3 NH N CH3
 C≡N	 NH CH3 N
 C≡N	 CO2H N
 Cl	 O O N CH3
 CH3O Cl	 O O N CH3
 O OH	 O N
 Cl	 O OH N
 Cl	 N O O CH3

 CH3O Cl	 N O O CH3
 CH3O Cl	 O OH N
 OCH3	 O OH N
 F F	 O OH N
 CH3	 O OH N
 CN	 O O OH N
 O O	 O OH N
 OCF3	 O OH N
 Cl F	 O OH N



8.-14. (Cancelled)

15. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1, optionally together with a pharmaceutically acceptable diluent or carrier.

16. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 6, optionally together with a pharmaceutically acceptable diluent or carrier.

17. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 7, optionally together with a pharmaceutically acceptable diluent or carrier.

18.-26. (Cancelled)